RCT-1213

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameRCT-1213
Drug Alias NameRCT1213RCT-1213
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTransmembrane 4 L6 family member 5 inhibitors
TargetsTransmembrane 4 L6 family member 5
Therapy Area/IndicationsColorectal NeoplasmsCarcinoma, HepatocellularCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesReCerise Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesReCerise Therapeutics IncNational Cancer Centre Singapore
Inactive CompaniesN/A
Active IndicationsColorectal NeoplasmsCarcinoma, HepatocellularCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A